Ge Healthcare Technologies INC

GE HealthCare Technologies Inc. has announced a strategic restructuring of its business segments, combining Imaging and Advanced Visualization Solutions into a new Advanced Imaging Solutions (AIS) segment, and has provided recast unaudited historical financial information.

GE HealthCare announced robust second quarter 2026 financial results, highlighted by record organic orders growth and a significant increase in backlog, while reaffirming full-year guidance.

GE HealthCare Technologies Inc. announced preliminary Q2 2026 financial results showing revenue growth and better-than-expected EPS, alongside the departure of CFO Jay Saccaro.

GE HealthCare Technologies Inc. held its annual meeting on May 7, 2026, where stockholders elected directors, approved executive compensation, and ratified auditor appointments, with subsequent board leadership changes.

GE HealthCare reported a 7.4% revenue increase for Q1 2026, driven by strong performance in key segments, but lowered its full-year profit and free cash flow outlook due to increased inflation.

GE HealthCare Technologies Inc. announced the appointment of Kevin A. Lobo, Chair and CEO of Stryker Corporation, to its Board of Directors, while two current directors will not seek re-election.

GE HealthCare reported a 5.7% increase in total revenues for Q2 2026, driven by its Advanced Imaging Solutions and Pharmaceutical Diagnostics segments, though net income attributable to GE HealthCare saw a decrease.

GE HealthCare reported a 7.4% increase in total revenues for Q1 2026, reaching $5.13 billion, but net income attributable to GE HealthCare decreased by 31.0% to $389 million.

GE HealthCare Technologies Inc. reported a 6% increase in Q3 revenues to $5.14 billion, but net income attributable to the company declined 5% to $446 million, impacted by cost inflation and tariffs.

GE HealthCare Technologies Inc. reported increased revenues, net income, and earnings per share for the second quarter and first half of 2025, driven by service growth and strategic acquisitions, despite macroeconomic headwinds and tariff impacts.

GE HealthCare Technologies Inc. announces its Q1 2025 financial results, including revenue growth and the acquisition of the remaining stake in Nihon Medi-Physics.

GE HealthCare's Q3 2024 results show a slight revenue increase but are impacted by challenges in the China market and ongoing global economic uncertainties.

GE HealthCare Technologies Inc. reported a 4.8% increase in total revenues for 2025, reaching $20.6 billion, driven by strong performance in its PDx, Imaging, and AVS segments, despite significant tariff impacts and a decline in its PCS segment.

GE HealthCare Technologies Inc. announces its fiscal year 2024 results, highlighting growth in key areas while addressing headwinds in the China market.

GE HealthCare Technologies Inc. has released its 10-K annual report for the fiscal year ended December 31, 2023, detailing its financial performance, business operations, and future outlook as a standalone company.

GE HealthCare Technologies Inc. reports a Form 4 filing detailing a Director's acquisition of common stock.

Jeannette Bankes, CEO of Patient Care Solutions at GE HealthCare Technologies Inc., reported a transaction involving the sale of 5,535 shares of common stock.

GE HealthCare Technologies Inc. director Rodney F. Hochman reported the acquisition of 1,618 shares of common stock on May 12, 2026.

GE HealthCare Director Phoebe L. Yang acquired 4,586 shares through a combination of an RSU grant and open market purchases.

GE HealthCare Technologies Inc. director H. Lawrence Culp Jr. acquired 7,743 shares through restricted and deferred stock unit awards.

GE HealthCare Technologies Inc. director Rodney F. Hochman acquired 6,275 shares through restricted and deferred stock unit awards.

GE HealthCare Technologies Inc. has released its 2026 Proxy Statement, outlining proposals for its upcoming annual meeting, executive compensation for 2025, and corporate governance updates.

GE HealthCare Technologies Inc. has announced its 2025 Annual Meeting and provided details on how stockholders can vote on key proposals.

GE HealthCare Technologies Inc. has announced the details for its 2025 Annual Meeting of Stockholders, including voting matters and board recommendations.

GE HealthCare Technologies Inc. announces its 2024 Annual Meeting to be held virtually on May 21, 2024, outlining key voting items for shareholders.

GE HealthCare Technologies Inc. has released its proxy statement for the 2024 Annual Meeting of Stockholders, detailing proposals for director elections, executive compensation approval, and auditor ratification.

Dodge & Cox has reported a beneficial ownership of 31,312,064 shares, representing 6.9% of the outstanding common stock of GE Healthcare Technologies Inc., as of March 31, 2026.

Capital Research Global Investors has filed a Schedule 13G, reporting beneficial ownership of 4.6% of GE HealthCare Technologies Inc. common stock as of March 31, 2026.

Vanguard Capital Management has reported a 7.31% beneficial ownership stake in GE HealthCare Technologies Inc.

The Vanguard Group reports zero beneficial ownership in GE HealthCare Technologies Inc. following an internal realignment.

Investment adviser Dodge & Cox has reported a 6.9% beneficial ownership stake in GE Healthcare Technologies Inc. common stock.

Capital Research Global Investors has reported a 5.5% beneficial ownership stake in GE HealthCare Technologies Inc., holding 24,972,556 shares of common stock.